论文部分内容阅读
探讨双重化疗术在中晚期肝癌的应用价值及门静脉导管保留术的实用价值；方法１５例中晚期肝癌患者采用经肝动脉的化疗药物灌注术和经皮经肝门静脉穿刺、门静脉化疗药物灌注术，其中１２例经矢状部穿刺行门静脉导管保留术，籍以反复进行化疗药物灌注，共行肝动脉化疗２２次，门静脉化疗４３次，导管保留时间自１５－３７天不等，平均为２４．２±７．６天。结果双重化疗使患者病情明显改善，生存期显著延长，疼痛显著减轻，ＡＦＰ下降，门脉压力下降，单叶肿瘤化疗效果显著优于双叶肿瘤，部份患者可争取手术切除。结论双重化疗是治疗中、晚期肝癌的有效办法，门静脉导管保留术是简便易行、临床实用的技术。
To explore the value of dual chemotherapy in the treatment of advanced hepatocellular carcinoma and the practical value of portal vein catheter preservation. Methods 15 patients with advanced hepatocellular carcinoma were treated with hepatic artery chemotherapeutic drugs, percutaneous transhepatic vein puncture, and portal vein chemotherapy perfusion. Twenty-two patients underwent portal vein catheter resection by sagittal puncture. The patients were treated with repeated chemotherapy and perfusion. Twenty-two of them received hepatic arterial chemotherapy and 43 of portal vein chemotherapy. The catheter retention time ranged from 15-37 days with an average of 24. 2±7.6 days. Results Double chemotherapy significantly improved the patient’s condition, significantly prolonged survival, significantly reduced pain, decreased AFP, and reduced portal pressure. The effect of single-leaf chemotherapy was significantly better than that of bifoliolates, and some patients could seek surgical resection. Conclusions Double chemotherapy is an effective method for the treatment of middle- and late-stage liver cancer. Portal catheter reservation is a simple, practical and practical technique.